# Exploratory Clinical Study on the Safety and Efficacy of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Myeloid Malignancies

> **NCT06917105** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Tongji Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Myeloid Malignancies
- CAR-T

## Interventions

- **DRUG:** CD33/CD123/CLL-1 CAR-T Cells

## Key facts

- **NCT ID:** NCT06917105
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2027-04-30
- **Final completion:** 2029-04-30
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06917105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06917105, "Exploratory Clinical Study on the Safety and Efficacy of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Myeloid Malignancies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06917105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*